| Budget Amount *help |
¥27,430,000 (Direct Cost: ¥21,100,000、Indirect Cost: ¥6,330,000)
Fiscal Year 2018: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2017: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2016: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
|
|---|
| Outline of Final Research Achievements |
Tumor blood vessels that supply the oxygen and nutrients to tumor tissues are necessary for tumor growth. Therefore, anti-angiogenic therapy has been considered promising therapeutic strategy for cancer treatment because inhibition of angiogenesis contributes to tumor progression. However, anti-angiogenic drug such as VEGF (Vascular endothelial growth factor) inhibitor have not bring remarkable therapeutic effects. In this study, we conducted research aimed at elucidating the Mechanisms of acquired resistance to anti-angiogenic therapy. As a result, we found a novel mechanism to acquire new tumor blood vessels by the movement of vessels. Moreover, we discovered that myeloid cell subsets are involved in the regulation of this phenomenon.
|
